Background: Controversy continues to surround the best practice for management of the axilla in patients with early breast cancer (EBC), particularly the clinically negative axilla. The balance between therapeutic and staging roles of axillary surgery (with the consequent morbidity of the procedures utilized) has altered. This is due to the increasing frequency of women presenting with early stage disease, the more widespread utilization of adjuvant chemoendocrine therapy and, more recently, the advent of alternative staging procedures, principally sentinel node biopsy (SNB). The aim of the present review is to critically analyse the current literature concerning the preferred management of the axilla in early breast cancer and make evidence-based recommendations on current management. Methods: A review was undertaken of the English language medical literature, using MEDLINE database software and crossreferencing major articles on the subject, focusing on the last 10 years. The following combinations of key words have been searched: breast neoplasms, axilla, axillary dissection, survival, prognosis, and sentinel node biopsy. Results: Despite the trend to more frequent earlier stage diagnosis, levels I and II axillary dissection remain the treatment of choice in the majority of women with EBC and a clinically negative axilla. Conclusions: Sentinel node biopsy has no proven superiority over axillary dissection because no randomized controlled trials have been completed to date. Despite this, SNB will become increasingly utilized due to encouraging results from major centres responsible for its development, and patient demand. Therefore if patients are not being enrolled in clinical trials strict quality controls need to be established at a local level before SNB is allowed to replace standard treatment of the axilla. Unless this is strictly adhered to there is a significant risk of an increase in the frequency of axillary relapse and possible increased understaging and resultant inadequate treatment of patients.
INTRODUCTION
Axillary surgery has an established role in staging and therapy for early breast cancer (EBC). [1] [2] [3] Despite this, the appropriate surgical management of the axillary lymph nodes (ALN) in EBC remains controversial. [4] [5] [6] [7] [8] [9] The nature of this controversy largely relates to the most appropriate method for surgically staging and treating the clinically negative axilla; when axillary dissection can be safely avoided in the clinically negative axilla; the current place of lymphatic mapping with sentinel node biopsy (SNB); and whether more extensive axillary treatment has a survival advantage in node-positive breast cancer.
Early breast cancer can be defined as the presence of a mobile tumour within the breast with or without associated mobile enlarged ALN, 10 and represents the vast majority of patients who present now with breast cancer. The descriptions of the anatomical level of axillary dissection used in the present paper are related to the pectoralis minor muscle with level I being below the lower border, level II behind the muscle and level III above the upper border of the muscle to the apex of the axilla. This discussion principally relates to those patients with EBC and a clinically negative axilla. This is because it is generally agreed that the appropriate treatment of the clinically and/or cytologically involved ALN is a well performed level II/III axillary dissection that both accurately stages and treats the axilla with minimal risk of local recurrence. 2, 3, 10, 11 Women with a clinically negative axilla now represent an increasing proportion of the breast cancer case load. 6 This is occurring because the proven benefit of mammographic screening programmes [12] [13] [14] [15] [16] is now widely accepted and the population has a greater awareness of breast cancer, resulting in more frequent earlier stage diagnoses. 6, [17] [18] [19] [20] [21] Until recently the frequency of histologically positive ALN in EBC has been of the order of 40-50%. [22] [23] [24] [25] [26] With the increasing percentage of small invasive (T 1 a and T 1 b) tumours, however, the percentage of women with postive ALN, and therefore the percentage actually receiving therapeutic benefit or having their treatment altered by the result of axillary dissection, may be reducing. Worldwide this situation will be accentuated in the future as more screen-detected cancers are identified. The evidence also suggests that screen-detected tumours, for any given size, may be associated with fewer ALN metastases than those detected in non-screened populations. 27, 28 Much of the momentum to obviate routine axillary dissection derives from reports in the literature of a low incidence of ALN positivity in patients with small invasive cancers, but these low rates are not verified by all authors, and up to 21% of T 1 tumours contain metastatic ALN disease on routine assessment, as shown in Table 1 . Furthermore many women with EBC are offered some form of chemoendocrine adjuvant therapy independent of ALN status based on the overview evidence from the Early Breast Cancer Trialists' Collaborative Group (EBCTCG). This recently updated study seems to demonstrate equivalent proportional benefit from adjuvant therapy independent of ALN status and age, [37] [38] [39] although these data are controversial and not entirely clear-cut when the unconfounded data are assessed. Therefore one could argue that there is a role for not surgically staging the axilla if the ALN status is not going to change the patient's management or if axillary surgery offers limited potential therapeutic benefit to that patient. Alternatively, staging the axilla by preoperative imaging or per-operatively with lesser procedures, most notably SNB in recent years, are other potential options. Sentinel node biopsy has been widely introduced in the USA and is increasingly utilized in many countries. 11, [40] [41] [42] This is despite the fact that there has not been randomized control trial evidence of its superiority over conventional management. But seemingly impressive non-randomized data from some enthusiastic centres and wide public appeal has driven this recent change into widespread practice. Indeed, even in the United Kingdom, where the Medical Research Council (MRC)-sanctioned study is still being set up, 43 some recent publications chose to discuss the next step after identifying a positive sentinel node rather than the place of the technique at all. 40, 44, 45 At the other extreme of axillary metastatic nodal involvement, it has recently been reported by several authors that when the ALN are heavily involved or the patient is at high risk of locoregional recurrence, radiotherapy to the chest wall and regional nodes following mastectomy and (limited) axillary dissection in premenopausal and postmenopausal women confers a survival advantage independent of the added benefit from systemic adjuvant therapy. [46] [47] [48] This recent evidence has re-challenged the current model of the biology of breast cancer spread and suggests that local control and ALN status is not just a marker of systemic disease, but that adequacy of local treatment and control can significantly affect overall survival. Whether or not an alteration in practice will occur as a result of these important studies remains to be seen.
AXILLARY STAGING The significance of axillary staging
The pathological data on breast tumour size, grade, oestrogen receptor status and ALN status taken in the context of the patient's age and menopausal status have formed the basis of clinical decision making in recent years. The ALN status has provided the single most reliable prognostic information on long-term recurrence-free and overall survival. 29, [49] [50] [51] [52] [53] It is well established that the incidence of ALN metastases is directly related to the size of the primary tumour 7,29,49,54,55 or, more specifically, to the size of the invasive component. 56 To a lesser extent it is related to the presence of lymphovascular invasion 52, 57, 58 and the grade of the primary tumour. 52, 59 Prognosis is also directly related to the absolute number of involved ALN as well as the anatomical level of involvement [49] [50] [51] [52] and possibly the presence of extranodal spread. [60] [61] [62] Recent evidence suggests that ALN status is not just a marker of chronology; that is, diagnosis at a later point in the natural history of the breast cancer, but also that ALN are an independent predictor of an aggressive tumour phenotype. 63 This was demonstrated by showing that patients with four or more ALN involved at diagnosis had a significantly worse outcome after relapse than node-negative cases regardless of the duration of the disease-free interval. 63 At presentation there is no specific way of identifying those tumours in which ALN status is more a reflection of chronology than a reflection of an aggressive phenotype, but these data suggest that an individual's ALN status is always a part of the spectrum of relative contribution between the two factors.
The reported number of ALN metastases in a specimen is dependent on the surgical technique and the method of histopathological nodal examination. 6, 64 Finer slicing and utilization of immunohistochemical staining increases the incidence of positive nodes detected by pathological assessment of the axillary nodes. But most of these occult new positive nodes contain only micrometastatic disease, 52, 65, 66 representing a focus of 0.25 mm diameter or less in more than 50% of cases. 52 Micrometastases have traditionally been defined as being 2 mm or less in diameter. 67 The biological clinical significance of occult ALN micrometastases detected by non-standard techniques is still debated, and more information from long-term follow up is needed. 28, 52, 53, 66, 68 The Ludwig Trial suggested that occult metastases detected by finer slicing of the ALN and standard haematoxylin and eosin (H&E) staining imply a worse prognosis, 52 but occult metastases detected by more sensitive tests (such as immunohistochemistry or reverse transcriptase-polymerase chain reaction (RT-PCR) to mRNA of an epithelial associated marker) are not proven to be associated with a worse prognosis. 53 This is particularly important now because increasing utilization of SNB and multiple sectioning of ALN are resulting in occult metastatic disease being reported more often. The reason for this is that the pathologist can now focus very carefully on a small number of lymph nodes rather than having to assess the entire axilla. 68 Reverse transcriptase-polymerase chain reaction to the mRNA of an epithelial associated marker has been shown to be more sensitive than immunohistochemistry in detecting otherwise occult metastases, but the significance of this is similarly unknown 69, 70 and it may be that these techniques will lead to a stage shift bias: the so-called Will Rogers Phenomenon. 71 This has been recently demonstrated by Schreiber et al., who showed that microstaging using cytokeratin immunohistochemical (CK IHC) staining of sentinel lymph nodes resulted in 9.4% of cases being upstaged from stage I to stage II. This microstaging was particularly noted in the tumours < 2 cm where 53.3% of node-positive patients with T 1 c or smaller lesions were detected by CK IHC. 72 The significance of otherwise occult micrometastatic disease detected by these highly sensitive immunohistochemistry and RT-PCR techniques, as well as the significance of micrometastases to bone marrow detected by similar methods, 73 needs further work. Hopefully the biological significance will be clarified by the ongoing American College of Surgeons' Oncology Group study of SNB, which assesses these factors as well. 74 Internal mammary nodes (IMN) are positive in the absence of 516 SPILLANE AND SACKS 32 8% 10% Cox et al. 33 Sentinel nodes 16% Silverstein et al. 7 3% 17% Silverstein et al. 7 Screen detected 4% 6% Tabar et al. 13 Screen detected 5% Walls et al. 34 Screen detected 3% Ductal carcinoma in situ
Silverstein et al. 35 0.6% Cox et al. 33 Sentinel node 4.6% Wong et al. 36 0/33 positive axillary nodes in 5-10% of cases and this is largely independent of primary tumour site. 10 From older series, between 24 and 37% of medial tumours have IMN involvement, but 13-22% of lateral tumours do so as well. [75] [76] [77] [78] There is evidence that in axillary node-negative breast cancer the presence of positive IMN is associated with a twofold greater risk of recurrence or death at 10 years. 79 The IMN status has become an often ignored aspect of staging in most centres, but the Nottingham Prognostic Index assesses the IMN in some cases. 80 The advent of SNB will result in the IMN and, occasionally, an intramammary lymph node being identified as the sentinel lymph node, and important management issues related to this will have to be addressed. 11, 81 The arguments for and against axillary dissection Level I and II axillary dissection remains the standard in EBC management in the clinically negative axilla, perhaps with the exception of certain very good prognosis groups such as patients with small T 1 low-grade tumours or 'special type' histopathology, especially those cases who are not eligible for adjuvant chemotherapy. 32, 82 In Recht and Houlihan's excellent review of the topic the data analysed suggested that removal of level I ALN alone is likely to accurately identify the great majority of patients who have axillary involvement, but there is a significant chance of undertreatment due to the higher level nodes being left behind. The morbidity of adding level II dissection to level I dissection is poorly quantified from the literature but it appears to be minimal. Therefore addition of level II axillary dissection detects and treats most remaining ALN-positive patients with minimal increased morbidity. 83 In Table 2 some common arguments for and against level I and II axillary dissection for staging in EBC are listed.
Advocates of complete axillary dissection would cite data suggesting that even though 91-96% of cases who have an involved ALN are identified by level I dissection, 49, 55 up to 50% of patients with ALN metastases at level I also have involved nodes at level II or III. 23, 49 If complete axillary dissection is not performed in the clinically negative axilla then higher level occult involved nodes and (occasionally) skip metastases can be missed. 2 Skip metastases are defined as the involvement of level II/III ALN in the absence of level I involvement. Veronesi et al. reported true skip metastases in only 1.3% of cases 24 but other authors have reported an incidence of 6% and rates even as high as 28%. 26, 98 This higher figure came from a study that was published 20 years ago, the results of which would have to be questioned in light of the volume of more recent evidence. Because complete axillary dissection is probably associated with a twofold increase in lymphoedema morbidity compared to lesser procedures 99 and there is no evidence of improved local control or staging, the addition of level III dissection is generally not recommended in the clinically negative axilla. 83 
Alternative axillary staging methods
Clinical assessment Clinical assessment of the axillary status is notoriously unreliable, giving high false positive and false negative rates of approximately 30%. 23, 100, 101 Triple node biopsy Triple node biopsy involves sampling of an internal mammary, axillary and apical lymph node. It was first The reported percentage of lymph node involvement in small tumours varies considerably but is up to 36% for small invasive tumours. 84 Higher prevalence of small invasive/non-invasive tumours results in more negative axillary dissections but the same attendant morbidity.
The number of ALN involved, 32 or even positive SNB, 85 alters the nature of adjuvant chemotherapy.
Most women get adjuvant chemotherapy independent of axillary node status. [37] [38] [39] High numbers of involved ALN is usually the entry criterion for enrolment in HDCT trials. 9 HDCT has no proven survival advantage. [86] [87] [88] Identification of high numbers of involved ALN results in advising locoregional RT with its improved local control and possible survival advantage. [46] [47] [48] 89 In the trials of SNB in EBC the sentinel node is the only one involved in 38-67% of cases. [90] [91] Full axillary dissection makes extranodal extension more likely to be detected. Hence the patient may benefit from RT for local control. 60, 92 Not proven. 83 Axillary lymph nodes status is still a major prognostic indicator following neoadjuvant chemotherapy. 93, 94 Neoadjuvant chemotherapy makes an alteration in treatment less likely after axillary dissection, 9,95-97 and may downstage axillary node status. 9 Information from axillary dissection is useful for audit and comparison of clinical trials of treatments and outcomes.
This may not benefit individual patients.
EBC, early breast cancer; ALN, axillary lymph node; SNB, sentinel node biopsy; HDCT, high-dose chemotherapy; RT, radiotherapy.
described by the Nottingham breast group 80 and is now utilized by other groups often with modification. 102, 103 Triple node biopsy has been shown to give very reliable prognostic information in EBC 80 but, in the absence of further axillary treatment, positive cases have a recurrence rate in the axilla of up to 21%. 104 Therefore if the biopsied ALN are positive the axilla should be dissected or radiotherapy given.
Axillary sampling Axillary sampling has been variously described as an anatomically imprecise, ill-defined procedure ranging from blind biopsy in the vicinity of the axillary tail through to a formal level I dissection. Kjaergaard et al. reported that, by their method of axillary sampling, in 40% of cases the sampled material contained insufficient or no lymph node tissue at all. 105 Other data have demonstrated that the procedure can be a reliable predictor of the ALN status. [106] [107] [108] Axillary sampling remains a commonly performed procedure (particularly in the United Kingdom) and reliably stages the axilla as long as at least four ALN are sampled. 107, 108 Twelve years after the Edinburgh trial closed there was no difference in the recurrence or survival rates between the axillary sampling and axillary dissection groups. 107 Even after adequately performed axillary sampling, the problem remains of how to treat the remaining ALN in patients with positive node sampling. This has been exemplified by a rate of arm swelling in excess of 30% when radiotherapy was added to the sampling; this resulted in some proponents of axillary sampling recommending completion axillary dissection as the preferred option rather than radiotherapy. 107 Intraoperative assessment by palpation and sampling of no more than four hard or enlarged lymph nodes followed by immediate frozen section and imprint cytological examinations had a false negative rate of 14% in one study; 109 an interesting comparison for the SNB data that follow here.
Sentinel node biopsy Lymphatic mapping identifies the anatomically defined first draining lymph node(s), called the sentinel node(s), after tracking blue dye or radiolabelled colloid (or both) that was injected around the primary tumour or its previous site. The sampling of these first draining ALN is SNB. Sentinel node biopsy has been shown by numerous investigators in nonrandomized case series to be a reasonably reliable predictor of axillary status. 33 113 The current expectation and, in some centres in the USA, the current practice, is for SNB to take over the role of axillary dissection for staging because it is associated with significantly less morbidity.
Major concerns with the widespread introduction of SNB are the learning curve for all surgeons (reported to involve approximately 20 cases), individual variability in surgeon's ability to locate the sentinel nodes, and concerns regarding certification and auditing of adequate performance. 11, 33, 54 In reality the individual surgeon needs to demonstrate an adequately low false negative rate (suggested to be at least below 10% 114 ) calculated on the number of false negatives divided by the total number of positive cases. The total number of cases is not the denominator and hence in reality the 'learning curve'-validation period should extend for approximately 20 positive cases, not just the first 20 cases, and during this period both SNB and axillary dissection should be performed. 114 Another concern with the primary concept of SNB was that if a sentinel node was fully replaced by tumour it may not retain radiolabelled colloid or blue dye. This was seen as one explanation for the reported false negative rates of up to 12%. 54 This may not be the case according to recent work by Kamath et al. in relation to melanoma where, despite gross nodal involvement, cutaneous lymphatic drainage patterns were maintained. 115 Other difficulties in sentinel node localization may also arise when the sentinel node is not in the axilla when blue dye is used, or if the primary tumour is very medial or lateral in the breast, making differentiation of the primary site hot spot on the lymphoscintigraphy difficult to separate from the sentinel node. 110 These reasons may explain the higher yield from combining both isosulphan blue dye and radiocolloid. 33 The reported false negative rate of up to 12% is not acceptable unless the real risk of axillary node involvement is very low for an individual patient, or the consequences of a false negative result do not significantly affect the individual patient's management. 54 There now needs to be further investigation of various aspects of the SNB technique such as the timing and dose of radiolabel injection; the ideal size of the particles in relation to these factors; and the significance of the various types of occult micrometastatic ALN disease. There is also a need for long-term follow up of local tumour control and patient survival when staged by this technique versus traditional axillary management. 11 Ideally this should be done as part of prospective randomized controlled trials. Hopefully the answers to some of the questions related to SNB will come as the four large studies currently being undertaken in the USA are published with adequate follow up, 74 as well as the UK study 43 and the European Organization for Research and Treatment of Cancer (EORTC) After Mapping of the Axilla: Radiotherapy or Surgery? (AMAROS) study reaching maturity. 116 The next step after identification of a positive sentinel node is similarly yet to be determined. Current alternatives include intraoperative frozen section and axillary dissection if positive, 40 touch prep cytology and axillary dissection if positive, 33 postoperative axillary radiotherapy or a second operation if the SNB is positive, and a 'watch policy'.
Non-operative axillary staging
Other modalities of preoperative imaging such as high resolution duplex and colour flow Doppler ultrasound, 117-119 magnetic resonance imaging, 120 positron emission tomography 121, 122 and sestamibi nuclear scanning 123, 124 have not been shown to reliably predict the ALN status to date.
Attempts to replace axillary staging by other prognostic indices
Numerous attempts to negate the value of axillary staging by providing equally reliable prognostic information by other methods have been made. The Fisher 'systemic concept' of breast cancer spread 125 conceptually weakens the idea that axillary status should remain the most reliable predictor of systemic disease. Ravdin et al. attempted to develop a prognostic index based on the United States National Breast Cancer Tissue Resource Data for nearly 12 000 women. The authors were unable to accurately predict ALN status using multivariate analysis with tumour size, patient age, S phase fraction and progesterone receptor level as the most sensitive combination of factors identified from their analysis. 126 Other factors assessed individually by other workers (partly in an attempt to make the prognostic information from axillary staging superfluous) without success include S phase fraction, 126 DNA ploidy, 127, 128 integrin expression, 129 serum CA 15-3 concentrations, 130 urokinase plasminogen activator concentration, 131 MUC 1 epithelial mucin expression level, 132 CD44 level, 133 cathepsin D levels, 134 cell cycle inhibitor p27 level 135 and c-erb B2 (or HER-2/neu) oncogene overexpression. 136, 137 Interestingly the expression of high levels of c-erb B2 has recently been shown to be an independent predictor of worse prognosis and is associated with poor response to chemotherapy. 136, 137 The receptor is being targeted for monoclonal antibody therapeutic intervention amid early non-randomized trial reports of survival benefit when used in combination with doxorubicin or taxanes. 137, 138 
AXILLARY SURGERY COMPARED TO AXILLARY RADIOTHERAPY AND NO AXILLARY TREATMENT
The National Surgical Adjuvant Breast and Bowel Project (NSABP) B04 Trial is the best evidence for comparison between the outcome from either axillary dissection, axillary radiotherapy and no axillary treatment. 22 This randomized controlled trial demonstrated no significant overall survival difference between the three groups of women with a clinically negative axilla who were assigned to either radical mastectomy, total mastectomy and irradiation of the axillary nodes, or simple mastectomy with delayed axillary dissection if nodes became clinically involved. The axillary relapse rate was 19% when the axilla was not treated. This rate of relapse when no treatment was given was much less than the 40% ALN positivity rate at histological assessment in the axillary dissection group. 22 This discrepancy is partly explained by many members of the non-axillary dissection group effectively having an axillary sampling as part of the 'simple' mastectomy performed and up to one-third of this group having an axillary dissection. 8, 139 Similar results were found in the Cancer Research Campaign (CRC; Kings/Cambridge) trial which demonstrated an increased local relapse rate without axillary treatment, but again no effect on overall patient survival. 140 In comparing axillary surgery to radiotherapy and no axillary treatment Table 3 assesses the therapeutic effectiveness of each option for local control, the incidence of morbidity, and long-term survival implications. One important aspect of effective axillary treatment is the avoidance of the rare but impossible-totreat scenario of uncontrolled axillary recurrence. The management of this eventuality is made more complicated by previous inadequate surgery or suboptimal radiotherapy. After review of several trials, some of which utilized orthovoltage techniques that would now be considered outdated, adjuvant radiotherapy was reported to be associated with a small increase in the rate of death from causes other than breast cancer. 157, 158 This excess of non-breast cancer deaths was mostly related to internal mammary fields involving heart and lung exposure. Unfortunately the best data on this issue would have come from the NSABP B04 Trial but these have not been published. The 1995 EBCTCG overview demonstrated no overall survival difference between radiotherapy versus axillary dissection to the axilla. 157 It is obvious from other studies that the incidence of local recurrence following radiotherapy or surgery depends on the adequacy of the treatment. For example, in NSABP B-04 Trial data axillary failure rates were 21, 12 and 0%, respectively, when 0, 1-5 or 6 or more negative lymph nodes were found in the axillary specimens. 162 There is mounting evidence that ineffective axillary treatment may have an adverse effect not only on disease-free survival, but also on overall survival. 4, 8, 146, 163 The corollary of this issue has been re-examined after recent publications suggested that radiotherapy after mastectomy may have a survival advantage in selected high-risk groups of premenopausal and postmenopausal women. [46] [47] [48] Some important confounding factors that have been suggested to lessen the current clinical applicability of these studies include the mean number of seven lymph nodes removed in the Danish axillary dissections (which many would not consider adequate); 141 and that the chemotherapy regimen used in both studies would now not be considered to be the optimum adjuvant treatment. The excess in cardiac mortality seen in the overview analysis 157 was not seen in these trials using modern planning techniques. What can be said with certainty is that these data raise interesting questions about the biology of breast cancer spread; they suggest that the ALN status is more than just a marker of systemic disease and that residual locoregional disease could act as a source of subsequent metastases. This has been addressed notably by Hellman in his Karnovsky Lecture, where he suggested a spectrum of biological behaviour between patients rather than the Halstedian step-wise or Fisher systemic concept of breast cancer spread. 164 This concept is further supported by a recently published retrospective study of well matched patients who were pathologically node negative at diagnosis. The investigators found that patients who had a limited axillary dissection with < 10 ALN removed had a significantly worse 5-year disease-free survival than those who had more extensive axillary surgery with ≥ 10 ALN removed (75.7 vs 86.2%; P ≤ 0.01); as well as a worse overall 5-year survival (84.5 vs 89.5%; P ≤ 0.05). 146 These data could possibly be explained by understaging in the < 10 ALN removed group (there were no data presented on the distribution of number of nodes in the < 10 nodes group) but, alternatively, may indicate that removal of micrometastases plays a role in conferring a better outcome. 146 
RECOMMENDATIONS
The surgical management of the axilla has to be determined locally on a case-by-case basis, making the decision when a fully informed patient expresses their wishes. The decision will depend on patient and tumour characteristics, the technology available and local expertise of the institution, and whether the patient has consented to take part in a properly designed prospective randomized controlled trial.
Early breast cancer with clinically negative axilla
A proposed schema for management of patients with EBC and a clinically negative axilla is outlined in Fig. 1 . In summary there is still a need to justify not performing a recognized effective method of axillary staging on a case-by-case basis because the axillary status is still the most reliable prognostic indicator for planning a patient's management. If the woman is at low risk of axillary disease and the result of axillary staging is highly unlikely to alter the management, then breast conservation surgery with radiotherapy to the breast and axilla or occasionally a 'watch' policy can be valid alternatives. If mastectomy is being performed then it would be sensible to perform a level I and II axillary dissection at that time. Before wholesale abandonment of a tried and proven surgical treatment is undertaken, well designed randomized controlled trials with adequate follow up should be completed that confirm that patients are not being put at higher risk for what is basically a low-morbidity procedure in experienced hands.
Early breast cancer with clinically involved axilla
Despite what are reported as acceptable levels of local recurrence in the clinically involved axilla treated with radiotherapy (< 10%), we consider that level II/III axillary dissection is the appropriate treatment in patients with a clinically (preoperatively and/or intraoperatively) or (as is occurring more often with better imaging) a cytologically positive axilla. Because radiotherapy fields applied to the supraclavicular fossa often extend to the coracoid process, many would argue that level III dissection is not necessary unless there are obviously involved nodes at that level. Level II/III axillary dissection gives good local control and full staging information. The role of adjuvant radiotherapy to the axilla when axillary dissection demonstrates a Increased non-breast cancer deaths 157, 158 No overall survival difference compared to axillary dissection 157 WC, wound complications; AS, arm swelling; CP, chronic pain; LSM, limitations shoulder movement; BP, brachial plexopathy; RIS, radiation-induced sarcoma; AD, axillary dissection; RT, radiotherapy; EBC, early breast cancer. Table 3 . Assessment of the axillary staging/treatment modalities and morbidity associated with their use in EBC Fig. 1 . Proposed management algorithm for axillary surgery in early breast cancer (EBC) with a clinically or cytologically negative axilla. DCIS, ductal carcinoma in situ; ER, oestrogen receptor; IDC, infiltrating ductal carcinoma..
Modality (reference)
Staging Local axillary recurrence rate Morbidity Survival benefit high number of nodes (> four usually) and/or extranodal spread should be made on a unit-by-unit basis after multidisciplinary agreement. There is no conclusive randomized controlled trial evidence of a survival advantage in these women because there is debate about both the extent of axillary surgery and the type of chemotherapy regimens used in the quoted studies, which may lessen the impact of their findings.
Advanced breast cancer
The place of axillary surgery in advanced breast cancer is beyond the scope of the present review, but there is an important role for axillary dissection in these patients as part of a planned multimodality attempt to gain optimal local tumour control and give prognostic information based on the number of nodes involved. 165 
